Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: The European Prospective Investigation into Cancer and Nutrition (EPIC)

Petra H M Peeters, Annekatrin Lukanova, Naomi Allen, Franco Berrino, Tim Key, Laure Dossus, Sabina Rinaldi, Carla H. Van Gils, H. Bas Bueno-de-Mesquita, Heiner Boeing, Mandy Schulz, Jenny Chang-Claude, Jakob Linseisen, Salvatore Panico, Carlotta Sacerdote, Domenico Palli, Rosario Tumino, Antonia Trichopoulou, Dimitrios Trichopolos, Christina BamiaNerea Larranaga, Eva Ardanaz, Guillem Pera, J. Ramón Quirós, Carmen Martínez-García, Carmen Navarro, Sheila A. Bingham, Kay Tee Khaw, Françoise Clavel, Anne Tjonneland, Anja Olsen, Kim Overvad, Mette S. Tetsche, Eiliv Lund, Eva Lundin, Göran Berglund, Elio Riboli, R. Kaaks

Research output: Contribution to journalArticlepeer-review


We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or younger, the relative risk was higher in the middle or top tertiles of serum IGF-I, when compared with women in the lowest tertile (odds ratios (OR)=1.8 (95%CI 0.7-4.3) and OR=2.4 (95%CI 0.9-6.4); Ptrend=0.08) respectively. These results were adjusted for body mass index, previous hormone use, fertility problems, and parity. Restricting the analysis to women who were premenopausal at blood donation, relative risks for ovarian cancer diagnosed before age 55 were higher (OR=5.1 (95%CI 1.5-18.2) and OR=5.6 (95%CI 1.5-20.8) respectively, for second and third tertiles; Ptrend=0.02). Adjustment for serum IGFBP-3 levels only slightly attenuated relative risk estimates. Relations between IGFBP-3 and ovarian cancer before age 55 were in the same direction as for IGF-I, but less strong and statistically not significant. In women aged over 55, there was no association between serum IGF-I or IGFBP-3 and ovarian cancer risk. Our results suggest that the circulating levels of IGF-I may play a potentially important role in the development of ovarian cancer in women of a pre- or perimenopausal age.

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalEndocrine-Related Cancer
Issue number1
Publication statusPublished - Mar 2007

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: The European Prospective Investigation into Cancer and Nutrition (EPIC)'. Together they form a unique fingerprint.

Cite this